Shared vision for improving patient and staff safety and minimizing waste
FRISCO, Texas, Nov. 12 /PRNewswire/ -- The convergence of a world-class sales and service organization and a manufacturing organization will allow both companies to drive new growth opportunities and ultimately transform the way cancer fighting drugs are prepared and administered. The combination of Primus Innovations, Inc. solutions, sales, and services with Health Robotics engineering, software and robotic chemotherapy compounding technology "CytoCare(TM)", will enable a new standard of precision, accuracy, safety, and price efficiencies in chemotherapy admixtures.
Jack Risenhoover, Health Robotics Managing Principal, described the trampoline effect of the combination as a "powerful tool in the battle against cancer. We are particularly pleased that Primus Innovations has selected CytoCare as its exclusive solution for chemotherapy compounding for hospitals and outpatient infusion centers. Primus' experience in outsourcing will be a significant advantage for CytoCare customers."
Steve Bohannon, Primus Innovations, Inc. CEO and President, said, "Health Robotics has designed an incredible product that tilts the scales in the battle against cancer. In CytoCare we have a rare triple win: more accurate infusions for patients, a far safer environment for pharmacists and technicians and better economics and regulatory compliance for hospitals, clinics and physicians. We are incredibly pleased to be the exclusive distributor and service provider for CytoCare in North America."
CytoCare provides unparalleled benefits for patients, staff and
pharmacists. The sterile robotic environment minimizes manual interaction
and the associated risk of contamination. It supports patient-specific
dosing, by using the patient's unique physical profile. Thus, the
medication regimen is tailored and accurate with swifter, more effective
|SOURCE Primus Innovations, Inc.|
Copyright©2007 PR Newswire.
All rights reserved